{"pmid":32400137,"title":"Management Practice of Allergic Rhinitis in China During the COVID-19 Pandemic.","text":["Management Practice of Allergic Rhinitis in China During the COVID-19 Pandemic.","Allergy Asthma Immunol Res","Zhang, Yuan","Zhang, Luo","32400137"],"journal":"Allergy Asthma Immunol Res","authors":["Zhang, Yuan","Zhang, Luo"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400137","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.4168/aair.2020.12.4.738","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666714494799183875,"score":9.490897,"similar":[{"pmid":32233040,"title":"Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement.","text":["Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement.","Allergy","Bousquet, Jean","Akdis, Cezmi","Jutel, Marek","Bachert, Claus","Klimek, Ludger","Agache, Ioana","Ansotegui, Ignacio J","Bedbrook, Anna","Bosnic-Anticevich, Sinthia","Canonica, Giorgio W","Chivato, Tomas","Cruz, Alvaro A","Czarlewski, Wienia","Del Giacco, Stefano","Du, Hui","Fonseca, Joao A","Gao, Yadong","Haahtela, Tari","Hoffmann-Sommergruber, Karin","Ivancevich, Juan C","Khaltaev, Nikolai","Knol, Edward F","Kuna, Piotr","Larenas-Linnemann, Desiree","Mullol, Joaquim","Naclerio, Robert","Ohta, Ken","Okamoto, Y","O'Mahony, Liam","Onorato, Gabrielle L","Papadopoulos, Nikos G","Pfaar, Oliver","Samolinski, Boleslaw","Schwarze, Jurgen","Toppila-Salmi, Sanna","Teresa Ventura, Maria","Valiulis, Arunas","Yorgancioglu, Arzu","Zuberbier, Torsten","32233040"],"journal":"Allergy","authors":["Bousquet, Jean","Akdis, Cezmi","Jutel, Marek","Bachert, Claus","Klimek, Ludger","Agache, Ioana","Ansotegui, Ignacio J","Bedbrook, Anna","Bosnic-Anticevich, Sinthia","Canonica, Giorgio W","Chivato, Tomas","Cruz, Alvaro A","Czarlewski, Wienia","Del Giacco, Stefano","Du, Hui","Fonseca, Joao A","Gao, Yadong","Haahtela, Tari","Hoffmann-Sommergruber, Karin","Ivancevich, Juan C","Khaltaev, Nikolai","Knol, Edward F","Kuna, Piotr","Larenas-Linnemann, Desiree","Mullol, Joaquim","Naclerio, Robert","Ohta, Ken","Okamoto, Y","O'Mahony, Liam","Onorato, Gabrielle L","Papadopoulos, Nikos G","Pfaar, Oliver","Samolinski, Boleslaw","Schwarze, Jurgen","Toppila-Salmi, Sanna","Teresa Ventura, Maria","Valiulis, Arunas","Yorgancioglu, Arzu","Zuberbier, Torsten"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32233040","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1111/all.14302","topics":["Treatment"],"weight":1,"_version_":1666138492206317568,"score":79.07132},{"pmid":32474406,"title":"The rediscovery of hydroxychloroquine in allergic diseases in the COVID-19 era.","text":["The rediscovery of hydroxychloroquine in allergic diseases in the COVID-19 era.","J Investig Allergol Clin Immunol","Bonzano, L","Cassone, G","Tarallo, L","Pellacani, G","32474406"],"journal":"J Investig Allergol Clin Immunol","authors":["Bonzano, L","Cassone, G","Tarallo, L","Pellacani, G"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474406","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.18176/jiaci.0575","keywords":["allergic diseases","covid-19","hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1668341932645941248,"score":43.256523},{"pmid":32426089,"pmcid":"PMC7229977","title":"Allergic respiratory disease care in the COVID-19 era: a EUFOREA statement.","text":["Allergic respiratory disease care in the COVID-19 era: a EUFOREA statement.","Spring and Summer 2020 are unique in that the challenges of care for those suffering from pollen allergy coincide with the COVID-19 pandemic. Several considerations are important to allow optimal care of allergic rhinitis (AR) and asthma and hence prevention of coronavirus spread through sneezing, rhinorrhoea and coughing. This compact overview of recommendations by the EUFOREA expert teams on allergic airway diseases and AIT is based on investigation of the current COVID-19 literature in association with the key words above and shared clinical experience of the experts involved. It deals with similarities and differences between AR and coronavirus infection, specific recommendations for allergic disease care in the COVID-19 era, including guidance on allergen specific immunotherapy, AIT.","World Allergy Organ J","Glenis K, Scadding","Peter W, Hellings","Claus, Bachert","Leif, Bjermer","Zuzana, Diamant","Philippe, Gevaert","Anette, Kjeldsen","Jorge, Kleine-Tebbe","Ludger, Klimek","Antonella, Muraro","Graham, Roberts","Andreas, Steinsvik","Martin, Wagenmann","Ulrik, Wahn","32426089"],"abstract":["Spring and Summer 2020 are unique in that the challenges of care for those suffering from pollen allergy coincide with the COVID-19 pandemic. Several considerations are important to allow optimal care of allergic rhinitis (AR) and asthma and hence prevention of coronavirus spread through sneezing, rhinorrhoea and coughing. This compact overview of recommendations by the EUFOREA expert teams on allergic airway diseases and AIT is based on investigation of the current COVID-19 literature in association with the key words above and shared clinical experience of the experts involved. It deals with similarities and differences between AR and coronavirus infection, specific recommendations for allergic disease care in the COVID-19 era, including guidance on allergen specific immunotherapy, AIT."],"journal":"World Allergy Organ J","authors":["Glenis K, Scadding","Peter W, Hellings","Claus, Bachert","Leif, Bjermer","Zuzana, Diamant","Philippe, Gevaert","Anette, Kjeldsen","Jorge, Kleine-Tebbe","Ludger, Klimek","Antonella, Muraro","Graham, Roberts","Andreas, Steinsvik","Martin, Wagenmann","Ulrik, Wahn"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426089","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.waojou.2020.100124","keywords":["ar, allergic rhinitis","covid-19","covid-19, coronavirus disease 2019","euforea, european forum for research and education in allergy and airway diseases","ins, intranasal corticosteroids","sar, seasonal allergic rhinitis","allergen immunotherapy","allergy","asthma","control","rhinitis","smell and taste","symptoms","treatment"],"topics":["Prevention"],"weight":1,"_version_":1667352728765988864,"score":41.937828},{"pmid":32500526,"title":"Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement.","text":["Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement.","The outbreak of the SARS-CoV-2-induced Coronavirus Disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant numberof the patients are on treatment with biologicals and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a \"cytokine storm\" and associated organ damage characterized by an exaggerated release of proinflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19 with studies focusing on severe allergic phenotypes lacking. At present, non-infected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management is demanded.","Allergy","Vultaggio, Alessandra","Agache, Ioana","Akdis, Cezmi A","Akdis, Mubeccel","Bavbek, Sevim","Bossios, Apostolos","Bousquet, Jean","Boyman, Onur","Chaker, Adam M","Chan, Susan","Chatzipetrou, Alexia","Feleszko, Wojciech","Firinu, Davide","Jutel, Marek","Kauppi, Paula","Klimek, Ludger","Kolios, Antonios","Kothari, Akash","Kowalski, Marek L","Matucci, Andrea","Palomares, Oscar","Pfaar, Oliver","Rogala, Barbara","Untersmayr, Eva","Eiwegger, Thomas","32500526"],"abstract":["The outbreak of the SARS-CoV-2-induced Coronavirus Disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant numberof the patients are on treatment with biologicals and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a \"cytokine storm\" and associated organ damage characterized by an exaggerated release of proinflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19 with studies focusing on severe allergic phenotypes lacking. At present, non-infected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management is demanded."],"journal":"Allergy","authors":["Vultaggio, Alessandra","Agache, Ioana","Akdis, Cezmi A","Akdis, Mubeccel","Bavbek, Sevim","Bossios, Apostolos","Bousquet, Jean","Boyman, Onur","Chaker, Adam M","Chan, Susan","Chatzipetrou, Alexia","Feleszko, Wojciech","Firinu, Davide","Jutel, Marek","Kauppi, Paula","Klimek, Ludger","Kolios, Antonios","Kothari, Akash","Kowalski, Marek L","Matucci, Andrea","Palomares, Oscar","Pfaar, Oliver","Rogala, Barbara","Untersmayr, Eva","Eiwegger, Thomas"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500526","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/all.14407","topics":["Prevention"],"weight":1,"_version_":1668890966306586624,"score":40.67904}]}